<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01243047</url>
  </required_header>
  <id_info>
    <org_study_id>COL012</org_study_id>
    <nct_id>NCT01243047</nct_id>
  </id_info>
  <brief_title>Intermittent Versus Continuous Tarceva Study</brief_title>
  <official_title>Intermittent Versus Continuous Erlotinib With Concomitant Modified 'Xelox' (q3W) in First-line Treatment of Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized phase II study comprising of two treatment arms in patients who are&#xD;
      previously untreated for metastatic or recurrent colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate two different schedules of erlotinib in combination with a modified XELOX regimen&#xD;
      in terms of response rate&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate two different schedules of erlotinib in combination with a modified XELOX regimen in terms of response rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate two different schedules of erlotinib and modified XELOX regimen in terms of toxicity, their duration of response and effect on time to progression, progression-free survival and overall survival.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the effect of intermittent versus continuous erlotinib administration on pharmacodynamic endpoints using tumor biopsies</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous erlotinib administration (21-day cycle). Erlotinib dose given at 100mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intermittent erlotinib administration (21-day cycle). Erlotinib dose given at 150mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Erlotinib, Oxaliplatin, Capecitabine</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  ECOG performance status of 0-2.&#xD;
&#xD;
          -  Histological proof of adenocarcinoma of colon or rectum with evidence of metastatic&#xD;
             disease.&#xD;
&#xD;
          -  At least one unidimensionally measurable lesion with a diameter &gt;20 mm using&#xD;
             conventional CT or MRI scans, or &gt; 10 mm with spiral CT&#xD;
&#xD;
          -  No prior drug treatment or chemotherapy for metastatic disease.&#xD;
&#xD;
          -  No prior HER2 or EGFR inhibitors. No prior Oxaliplatin in any clinical setting.&#xD;
&#xD;
          -  Absolute granulocyte count &gt; 1.5 x 109/L, platelet count &gt; 100 x 109/L, hemoglobin&#xD;
             level &gt; 9.0 g/L, INR &lt; 1.5.&#xD;
&#xD;
          -  Adequate renal &amp; hepatic functions: serum creatinine &lt; 1.5 x upper limit of normal&#xD;
             (ULN) or calculated creatinine clearance &gt; 50ml/min, serum bilirubin &lt; 1.5 x ULN, ALT&#xD;
             &lt; 2.5 x ULN or &lt; 5 x ULN in case of liver metastases, albumin level &gt; 30g/dL).&#xD;
&#xD;
          -  Prior adjuvant or neoadjuvant chemotherapy for non-metastatic CRC is allowed if &gt; 3&#xD;
             months has elapsed since the last dose of chemotherapy.&#xD;
&#xD;
          -  Prior open surgery is allowed if &gt; 28 days* has elapsed since the date of surgery,&#xD;
             wound healing is satisfactory and recovery from any complications from the surgery is&#xD;
             adequate. (*For laparoscopic surgery, &gt; 14 days from the date of surgery).&#xD;
&#xD;
          -  No serious medical conditions such as myocardial infarction within 6 months prior to&#xD;
             entry, or any other medical conditions that might be aggravated by treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of any malignancies, except basal cell cancer of skin, cervical CIN.&#xD;
&#xD;
          -  Treatment with radiotherapy &lt; 30 days.&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Sexually active males and females (of childbearing potential) unwilling to practice&#xD;
             contraception during the study.&#xD;
&#xD;
          -  Patients who have not recovered from surgery or other medical illness such as&#xD;
             infection.&#xD;
&#xD;
          -  Evidence of central nervous system disease. Patients with a history of uncontrolled&#xD;
             seizures, central nervous disorders or psychiatric disability judged by the&#xD;
             investigator to be clinically significant precluding informed consent or interfering&#xD;
             with compliance for oral drug intake should be excluded from the study&#xD;
&#xD;
          -  Patients lacking physical integrity of upper gastrointestinal tract or malabsorption&#xD;
             syndrome or unable to swallow tablets.&#xD;
&#xD;
          -  Prior unanticipated severe reaction to fluoropyrimidine therapy (with or without&#xD;
             documented DPD deficiency).&#xD;
&#xD;
          -  Interstitial pneumonia or extensive symptomatic fibrosis of the lungs.&#xD;
&#xD;
          -  Requirement for concurrent use of the antiviral agent sorivudine (antiviral) or&#xD;
             chemically related analogues, such as brivudine.&#xD;
&#xD;
          -  Known peripheral neuropathy ≥ NCI CTC grade 1.&#xD;
&#xD;
          -  Current or recent (within 10 days prior to study treatment start) use of full-dose&#xD;
             oral anticoagulant (e.g. warfarin) or thrombolytic agent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigette Ma, MD, FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Oncology, The Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Oncology, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2010</study_first_posted>
  <last_update_submitted>November 20, 2012</last_update_submitted>
  <last_update_submitted_qc>November 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>CCTU</investigator_full_name>
    <investigator_title>Comprehensive Clinical Trial Unit</investigator_title>
  </responsible_party>
  <keyword>Second line treatment for metastatic colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

